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Outbreak of infectious bursal disease (IBD) in chickens due to highly pathogenic strain of 
IBD virus (vvIBDV) was first reported in Europe in late 1980’s and in Malaysia in 1991. 
The disease caused significant economic losses, estimated more than RM72 million per 
year in Malaysia alone due to high mortality and immunosuppression. Treatment of IBD 
is of no value and the disease can only be controlled and prevented by proper vaccination 
programme and biosecurity. It was the objectives of the study to determine the molecular 
characteristic of Malaysian field isolates of IBDV and expression of the VP2 gene of the 
isolate for the development of diagnostic kit and recombinant vaccine. Three IBDV 
isolates identified as UPM04178, UPM04190 and UPM04238 were characterised. Based 
on their pathogenicity and sequence characteristic, the highest similarity (98%) 
concerning both nucleotide and amino acid sequences, the IBDV isolates were 
characterized as vvIBDV strains. Evolutionary relatedness of the isolates to vvIBDV 
strains was demonstrated by three phylogenetic methods: bootstrap values of 100%, 95% 
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and 90% for nucleotide sequences and those of 58%, 86% and 96% for amino acid 
sequences were obtained by the distance, maximum parsimony and maximum likehood 
methods, respectively. Phylogenetic analysis revealed clustering of the isolates with 
vvIBDV strains of serotype 1, which originate from a common ancestor of IBDV strains 
present in Malaysia.  
 
Using informative characteristics of the isolate, both diagnostic kit and recombinant 
vaccine were successfully developed using a new wild-type field vvIBDV strain of 
UPM04190 isolate. A safe and effective recombinant IBD vaccine was developed base 
on the construction of recombinant VP2 gene of the isolate cloned into an Escherichia 
coli expression system. The VP2 gene was inserted into pRSET B vector as a fusion 
protein with histidine tag, which can be easily purified. The recombinant VP2 protein 
bands were expressed to their expected sizes of ~50 kDa from cell lysate. The pRSET 
vectors are pUC-derived expression vectors and expression of the gene of interest from 
pRSET is controlled by the strong phage T7 promoter that drives expression of gene 10 
(Φ10) which provides protein stability and help to maintain the original structure of the 
protein. High-level production (3 mg/ml) of soluble product of VP2 recombinant protein 
was achieved with modified techniques of expression conditions and approaches. 
Efficacy test demonstrated that the recombinant vaccine of various fractions could 
provide protection ranging from 75% to 100% in highly susceptible chickens (specific 
pathogen free chickens) when challenged with vvIBDV (B00/81) at 104.25 EID50/ml per 
chicken following vaccination. One-step-immunostrip kit which is highly specific and 
sensitive was developed using whole virus as capture antigen and high-affinity polyclonal 
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IBD antibodies coated with gold particles. Rapid detection of IBD antibody can be 
achieved as fast as two minutes in a clinical or field environment. The kit is highly 
sensitive as it can detect as low as 250 ELISA units compared to commercial ELISA kit 
that only goes to 391 ELISA units for positive samples. The specificity of the kit was 
evaluated against antibody of other chicken viruses. No signal of reactivity or cross react 
exists among the antibodies tested.  Thus, it was highly specific to IBDV. It was 
concluded that the local IBDV isolates were proven to be vvIBDV strain, the constructed 
recombinant vaccine provide a safe and effective protection and, the developed one-step-
immunostrip kit is rapid, specific, sensitive, safe and economic in detection of IBDV 
infection and monitoring immune status of chicken against IBD. 
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Wabak penyakit bursa berjangkit (IBD) pada ayam disebabkan oleh strain virus IBD 
(IBDV) yang sangat patogenik buat pertama kali dilaporkan di Eropah lewat 1980-an dan 
di Malaysia pada 1991. Penyakit ini menyebabkan kerugian ekonomi secara signifikan, 
jangkaan kerugian disebabkan kematian dan depresi yang tinggi di Malaysia sahaja 
melebihi RM72 juta setahun. Rawatan terhadap IBD adalah sia-sia dan penyakit tersebut 
hanya boleh dikawal dan dicegah melalui program vaksinasi yang betul dan keselamatan 
secara biologi. Oleh itu, matlamat pengajian kini adalah untuk mengenalpasti ciri-ciri 
isolat IBDV daripada lading ayam di Malaysia dan pengekspresan protin VP2 bagi isolat 
tersebut untuk digunakan dalam pembangunan kit analisa dan vaksin rekombinan. Tiga 
isolate virus yang dikenalpasti sebagai UPM04178, UPM04190 dan UPM04238 telah 
dicirikan. Berdasarkan kepatogenan dan ciri-ciri jujukan, kesamaan tertinggi (98%) yang 
memberi tumpuan kepada kedua-dua jujukan nukleotida dan asid-asid amino adalah 
dicirikan sebagai strain sangat virulen IBDV (vvIBDV). Hubungan secara evolusi bagi 
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ketiga-tiga isolat terhadap strain vvIBDV ditunjukkan oleh tiga kaedah filogenetik iaitu 
nilai bootsrap 100%, 95% dan 90% bagi jujukan nukleotida dan; 58%, 86% dan 96% bagi 
jujukan asid amino yang didapati daripada kaedah “distance”, “maximum parsimony” 
dan “maximum likelihood” setiap satunya. Analisis filogenetik menyimpulkan bahawa 
ketiga-tiga isolat adalah dikelaskan kepada strain vvIBDV serotaip 1, dimana ianya 
berasal daripada keturunan strain IBDV yang biasa didapati di Malaysia. 
 
Berbekalkan ciri-ciri berguna bagi isolat tersebut, kedua-dua kit analisa dan vaksin 
rekombinan telah berjaya dibangunkan menggunakan strain virulen isolat UPM04190 
IBDV liar. Vaksin rekombinan IBD yang selamat dan efektif telah dibangunkan 
berasaskan pembinaan gen VP2 rekombinan bagi isolat tersebut yang diklonkan ke dalam 
system pengekspresan Escherichia coli. Gen VP2 bagi isolat ini dimasukkan ke dalam 
vektor pRSET B  sebagai protein fusion bersama-sama tag histidin, di mana ianya mudah 
dibersihkan. Pengekspresan jalur protein VP2 rekombinan adalah pada saiz yang 
dijangkakan iaitu ~50 kDa daripada lysate sel. Vektor-vektor pRSET adalah merupakan 
vektor pengekspresan hasilan-pUC dan pengekspresan gen yang diminati daripada vektor 
pRSET dikawal oleh promoter T7 faj yang kuat yang mengaturkan pengekspresan gen 10 
(Ф10) dimana ianya membekalkan kestabilan protein dan membantu mengekalkan 
struktur asal protein. Penghasilan produk terlarut yang tinggi (3 mg/ml) bagi protein VP2 
rekombinan dicapai melalui teknik-teknik pembaharuan bagi kepelbagaian keadaan 
pengekspresan dan juga permintaan. Ujian keberkesanan menunjukkan bahawa vaksin 
rekombinan daripada pelbagai pecahan mampu memberi perlindungan pada had 75% 
sehingga 100% pada ayam yang sangat berpotensi (ayam bebas pathogen tertentu) 
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apabila dicabar dengan 104.25 EID50/ml vvIBDV (B00/81) setiap ayam sejurus vaksinasi. 
Kit “one-step-immunostrip” yang sangat spesifik dan sensitif telah dibangunkan 
menggunakan keseluruhan virus sebagai antigen penangkapan dan poliklonal antibodi 
IBD berkeafinitian tinggi yang dilapisi dengan partikel emas. Pengenalpastian yang 
pantas bagi antibodi IBD boleh dicapai sepantas dua minit dalam persembahan klinikal 
atau ladang. Kit tersebut sangat sensitif hingga mampu mengesan serendah 250 unit 
ELISA berbanding kit ELISA komersial yang hanya mampu mengesan 391 unit ELISA 
bagi sampel positif. Ketepatan sistem jalur ujian berasas pepejal dinilai bersandarkan 
virus-virus ayam. Antibodi virus ayam tersebut yang duji terhadap IBDV yang 
terperangkap tidak menunjukkan sebarang isyarat dan tindak balas. Oleh itu, ianya sangat 
spesifik terhadap IBDV. Kesimpulannya, keputusan yang didapati menunjukkan isolat-
isolat  tempatan adalah merupakan strain vvIBDV, vaksin rekombinan yang dibina adalah 
selamat dan berkesan dalam memberi perlindungan dan, pembangunan kit “one-step-
immunostrip” adalah pantas, spesifik, sensitif, selamat dan ekonomik dalam 
pengenalpastian jangkitan IBDV, dan pengawalan status imun IBD pada ayam.  
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